These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 29445178

  • 1. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ.
    Sci Rep; 2018 Feb 14; 8(1):2964. PubMed ID: 29445178
    [Abstract] [Full Text] [Related]

  • 2. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar 14; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T, Zeng H, Long Y, Li X, Sun X, Lan Y, Gao L, Zhang L, Feng Z, Hou X.
    Trials; 2020 Jun 30; 21(1):597. PubMed ID: 32605578
    [Abstract] [Full Text] [Related]

  • 4. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP.
    BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486
    [Abstract] [Full Text] [Related]

  • 5. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.
    Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P.
    Gastroenterology; 2017 Aug 25; 153(2):448-459.e8. PubMed ID: 28483500
    [Abstract] [Full Text] [Related]

  • 6. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J, De Looze D.
    Gastroenterology; 2021 Jan 25; 160(1):145-157.e8. PubMed ID: 32681922
    [Abstract] [Full Text] [Related]

  • 7. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, Kim M, Keller MJ.
    Lancet Gastroenterol Hepatol; 2019 Sep 25; 4(9):675-685. PubMed ID: 31326345
    [Abstract] [Full Text] [Related]

  • 8. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.
    Gastroenterol Clin Biol; 2008 Feb 25; 32(2):147-52. PubMed ID: 18387426
    [Abstract] [Full Text] [Related]

  • 9. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.
    Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, Patel J, Jadon PS, Pandit A, Dargad RR, Khanna S, Kumar S, Day R.
    Gut Microbes; 2024 Feb 25; 16(1):2338322. PubMed ID: 38630015
    [Abstract] [Full Text] [Related]

  • 10. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM.
    Gut; 2018 Dec 25; 67(12):2107-2115. PubMed ID: 29980607
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
    Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ.
    J Clin Gastroenterol; 2011 Sep 25; 45(8):679-83. PubMed ID: 21301358
    [Abstract] [Full Text] [Related]

  • 12. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B.
    Nutrients; 2021 Feb 26; 13(3):. PubMed ID: 33652763
    [Abstract] [Full Text] [Related]

  • 13. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kosikowski W, Szczerbiński M, Gantzel J, Cukrowska B.
    Nutrients; 2020 Jul 05; 12(7):. PubMed ID: 32635661
    [Abstract] [Full Text] [Related]

  • 14. The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors.
    Lin H, Guo Q, Wen Z, Tan S, Chen J, Lin L, Chen P, He J, Wen J, Chen Y.
    Microb Cell Fact; 2021 Dec 28; 20(1):233. PubMed ID: 34963452
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS.
    Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, Halpern Z, Maharshak N, Dekel R.
    Neurogastroenterol Motil; 2017 Jul 28; 29(7):. PubMed ID: 28271623
    [Abstract] [Full Text] [Related]

  • 16. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
    Guglielmetti S, Mora D, Gschwender M, Popp K.
    Aliment Pharmacol Ther; 2011 May 28; 33(10):1123-32. PubMed ID: 21418261
    [Abstract] [Full Text] [Related]

  • 17. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG.
    J Gastroenterol Hepatol; 2014 Jan 28; 29(1):52-9. PubMed ID: 23829297
    [Abstract] [Full Text] [Related]

  • 18. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome.
    Hod K, Dekel R, Aviv Cohen N, Sperber A, Ron Y, Boaz M, Berliner S, Maharshak N.
    Neurogastroenterol Motil; 2018 Dec 28; 30(12):e13456. PubMed ID: 30136337
    [Abstract] [Full Text] [Related]

  • 19. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
    Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J.
    World J Gastroenterol; 2014 Jul 14; 20(26):8709-16. PubMed ID: 25024629
    [Abstract] [Full Text] [Related]

  • 20. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.
    Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK.
    Nutr J; 2016 Feb 27; 15():21. PubMed ID: 26922379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.